论文部分内容阅读
目的分析高迁移率族蛋白B1(HMGB1)及晚期糖基化终产物受体(RAGE)蛋白在卵巢癌组织中的表达及其与临床病理相关因素的关系。方法选取2010—2015年齐齐哈尔市第一医院和齐齐哈尔医学院附属医院卵巢癌标本存档蜡块45例为A组,卵巢良性肿瘤标本存档蜡块37例为B组。采用免疫组织化学技术检测两组HMGB1和RAGE的表达情况,分析其表达与卵巢癌组织的病理分级、临床分期、淋巴结转移等临床病理因素的关系。结果 HMGB1及RAGE在A组中的阳性表达率分别为77.8%(35/45)和71.1%(32/45);在B组中的阳性表达率分别为10.8%(4/37)和16.2%(6/37);组间比较,差异均有统计学意义(P<0.05)。卵巢癌病理分级、淋巴结转移与HMGB1及RAGE高表达有密切关系(P<0.05);HMGB1与RAGE基因表达呈正相关(P<0.05)。结论 HMGB1和RAGE基因表达与卵巢癌临床病理学特征密切相关,HMGB1/RAGE信号通路可能参与卵巢癌的转移,可作为临床卵巢癌药物治疗的重要候选靶点。
Objective To analyze the expression of high mobility group box 1 (HMGB1) and advanced glycation end product receptor (RAGE) proteins in ovarian cancer and its relationship with clinicopathological factors. Methods Forty-five cases of paraffin blocks in ovarian cancer specimens from the First Hospital of Qiqihar City and the Affiliated Hospital of Qiqihar Medical College from 2010 to 2015 were selected as Group A, and 37 cases of paraffin-embedded ovarian benign tumor samples were selected as Group B. Immunohistochemistry was used to detect the expression of HMGB1 and RAGE in two groups. The relationship between the expression of HMGB1 and RAGE was analyzed with the clinicopathological factors including pathological grade, clinical stage and lymph node metastasis of ovarian cancer. Results The positive rates of HMGB1 and RAGE in group A were 77.8% (35/45) and 71.1% (32/45), respectively. The positive rates of HMGB1 and RAGE in group A were 10.8% (4/37) and 16.2% (6/37). There were significant differences between groups (P <0.05). Ovarian cancer pathological grade, lymph node metastasis and high expression of HMGB1 and RAGE are closely related (P <0.05); HMGB1 and RAGE gene expression was positively correlated (P <0.05). Conclusion The expression of HMGB1 and RAGE is closely related to the clinicopathological features of ovarian cancer. The HMGB1 / RAGE signaling pathway may be involved in the metastasis of ovarian cancer, which may serve as an important candidate for clinical treatment of ovarian cancer.